Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Petr Kavan
Name of drug and indication under review:	Trifluridine and Tipiracil (Lonsurf)

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- · affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - 🛛 Yes
 - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - ☑ Advisory role (e.g., advisory boards, health technology assessment submission advice)
 ☑ Conference attendance
 ☑ Royalties
 ☑ Travel grants
 - Gifts
 Sponsorship of events
 - □ Honoraria □ Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Taiho Pharma Canada:

CAD as part of an educational grant for GI Cancer Workshops (a multicompany supported educational workshops aimed to educate healthcare professional involve with GI cancer patients). Advisory meetings.

Conference attendance.



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

2019-09-09

Petr Kavan



Date

Name

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Ronald Burkes
Name of drug and indication under review:	Lonsurf

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- · affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - 🛛 Yes
 - 🗆 No

Honoraria

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, health technology assessment submission advice)	 Program or Operating Funding (e.g., website)
Conference attendance	Research/educational grants
□ Royalties	Travel grants
□ Gifts	Sponsorship of events

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Taiho

Other, please specify:

Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

13/9/19

Date

Ronald Burkes

Name

1

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:

Name of drug and indication under review:

Christine	Brizden-Mastey
	(Lonsurf) - Metastatic Gastric Canar

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - l Yes □ No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

1	Advisory ro	le (e.g.,	advisory	boards,	health
	technology	assessi	ment sub	mission	advice)

 Program or Operating Funding (e.g., website)

- Conference attendance
- Royalties
- □ Gifts
- 🛛 Honoraria

- Research/educational grants
- Travel grants
- Sponsorship of events
 - □ Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.



Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.



Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NA

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

Sep 17/19	C. Brugdon - M coly	
Date	Name	Signature

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Howard Lim
Name of drug and indication under review:	Trifluridine and Tipiracil (Lonsurf)

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - 🛛 Yes
 - 🗆 No

☐ Honoraria

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, health technology assessment submission advice)	 Program or Operating Funding (e.g., website)
Conference attendance	Research/educational grants
□ Royalties	⊠ Travel grants
□ Gifts	□ Sponsorship of events

- Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Roche \$, Bayer \$, BMS \$, Amgen \$, Lilly \$, Taiho \$, Eisai \$, Ipsen \$



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

N/A

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

September 16, 2019

Howard Lim

Date

Name

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Hatim Karachiwala
Name of drug and indication under review:	TAS102

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - ⊠ Yes □ No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

🗆 Honoraria	☑ Other, please specify: Speaker
Gifts	☑ Sponsorship of events
□ Royalties	Travel grants
Conference attendance	Research/educational grants
 Advisory role (e.g., advisory boards, health technology assessment submission advice) 	 Program or Operating Funding (e.g., website)

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Tahio - \$	and a start of the second s	in the second second second second second

Clinician Input Template for CADTH pan-Canadian Oncology Drug Review Program

Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

September 10th 2019 Date Hatim Karachiwala

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Mark Vincent FRCPC
Name of drug and indication under review:	Lonsurf: stomach and GE junction cancer

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - 🛛 Yes
 - 🗆 No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, health technology assessment submission advice)	 Program or Operating Funding (e.g., website)
Conference attendance	Research/educational grants
□ Royalties	□ Travel grants
□ Gifts	Sponsorship of events
⊠ Honoraria	Other, please specify:

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Taiho Canada inc. Advisory Board honoraria at standard rates amounting to approximately spefr annum for the last 2 years.



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

13 September 2019

Mark Vincent



Date

Name

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	SHARLENE GILL
Name of drug and indication under review:	TRIFLURIDINE/TIPIRACIL – ADVANCED GASTRIC CANCER

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
 - 🛛 Yes
 - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - ☑ Advisory role (e.g., advisory boards, health technology assessment submission advice)
 □ Program or Operating Funding (e.g., website)
 - □ Conference attendance □ Research/educational grants
 - Royalties
 - Gifts
 - 🛛 Honoraria

- □ Travel grants
- Sponsorship of events
 - Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

TAIHO CANADA - advisory board honoraria - less than \$

CAD over past 12 months.



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

NA

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NA

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

Sep 14, 2019

Sharlene Gill

Date

Name

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Dr. Jennifer Spratlin
Name of drug and indication under review:	Trifluridine and Tipiracil (Lonsurf)

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency - it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

Have you received any payments over the previous two years from any company or organization that may have a direct or 1. indirect interest in the drug under review?




If no, please go to Section B.

What form of payment did you receive? (Check all that apply.) 2.

Advisory role (e.g., advisory boards, health technology assessment submission advice)	 Program or Operating Funding (e.g., website)
Conference attendance	Research/educational grants
□ Royalties	Travel grants
🗆 Gifts	Sponsorship of events
Altonoraria	□ Other, please specify:

Please provide the names of companies and organizations, and the amounts of the payments, in the following box. 3.



Section B: Holdings or Other Interests

potential, or perceived conflict of interest situation.

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.



NA

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real,

September 16, 2019

Jennifer Spratlin

Date

Name